Coloplast B

Deutsche Bank cuts Coloplast’s target price to 460 DKK, citing market volatility yet maintains a positive view of its fundamentals and growth prospects.

Coloplast’s latest quarter shows earnings dip and goodwill write‑down, prompting banks to cut price targets and re‑evaluate the Kerecis acquisition’s upside.

Barclays and Jyske Bank cut their target prices for Coloplast to DKK 500 and DKK 530, respectively, signalling a balanced outlook amid earnings expectations and market shifts in the medical‑device sector.

Coloplast’s new CEO, Gavin Wood, faces U.S. reimbursement shifts while chasing €3bn growth under Impact 4, blending digital health, cost discipline and value‑based contracts to protect margins.

Coloplast’s new CEO, Gavin Wood, is steering the Danish healthcare group toward digital innovation, tiered pricing, and value‑based reimbursement—boosting margins, expanding market share in chronic‑care and urology, and keeping debt low for sustaina…

Coloplast names Gavin Wood as CEO, a move that could steer the Danish medical‑device firm toward digital health, faster approvals, and higher growth while balancing cost efficiency.

Coloplast names Gavin Wood, a Johnson & Johnson veteran, as CEO – a strategic move to boost product pipeline, market reach and operational efficiency in medical technology.

Coloplast A/S thrives amid market volatility, backed by robust finances, a diversified product portfolio, and strategic moves like the Kerecis deal.

Coloplast B’s share price has declined due to downward revisions from leading financial institutions, but the company’s strategic overhaul and solid fundamentals suggest it remains well-positioned for long-term growth.